Phase I Biomarker Study (BMS-936558)

Clinical Trial ID NCT01358721

PubWeight™ 67.22‹?›

🔗 Visit the page for NCT01358721

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012 52.99
2 Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013 3.48
3 Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2013 2.64
4 The Impact of Tonsillectomy upon the Risk of Oropharyngeal Carcinoma Diagnosis and Prognosis in the Danish Cancer Registry. Cancer Prev Res (Phila) 2015 2.17
5 Antagonists of PD-1 and PD-L1 in Cancer Treatment. Semin Oncol 2015 1.45
6 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
7 Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer. Cancer J 2014 0.88
8 Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clin Cancer Res 2016 0.86
9 PD-1 blockade in renal cell carcinoma: to equilibrium and beyond. Cancer Immunol Res 2014 0.85
10 Evolving Concepts: Immunity in Oncology from Targets to Treatments. J Oncol 2015 0.81
11 Influence of tumors on protective anti-tumor immunity and the effects of irradiation. Front Oncol 2013 0.79
12 Cellular and molecular immunology of lung cancer: therapeutic implications. Expert Rev Clin Immunol 2014 0.79
13 Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015. J Transl Med 2016 0.77
14 Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma. ESMO Open 2016 0.77
15 New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 2015 0.76
16 An update on current management of advanced renal cell cancer, biomarkers, and future directions. Ann Cancer Res 2015 0.76
17 Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions. BioDrugs 2014 0.76
Next 100